Researchers are attempting to establish how to make long-term HIV remission possible after finding that HIV can be suppressed naturally in some people for a long time after they have been on a short spell of treatment.
An update on long-acting formulations of cabotegravir and rilpivirine, which are being tested in clinical trials.
The noted HIV researcher reflects on recent advances, the search for a cure, and the long road ahead.
Bictegravir, an emerging integrase inhibitor that is co-formulated with two other anti-HIV drugs, showed an efficacy similar to Tivicay (dolutegravir) in a phase III clinical trial.
Sanjabi talks about her early interest in science, her innovative research toward an HIV cure, and the importance of mentoring early career investigators.
Researchers estimated a total body burden of as many as seven million cells expressing HIV RNA at any given time in tissues, despite viral load suppression to undetectable levels in the blood.
Two oral presentations and numerous posters at the 16th European AIDS Conference included new data on using dolutegravir-based dual ART (many with 3TC) as a switch option for people currently on stable three-drug ART.
Signal That ABX464 Reduces Viral Reservoir but Not Time to Viral Rebound After Treatment Interruption
New data presented at EACS 2017 suggested that the investigational REV inhibitor ABX464 might reduce the HIV viral reservoir in a study that included a treatment interruption.
Other Names: 744 LA, CAB, GSK-1265744, GSK1265744, GSK744, GSK744 LA, GSK744 LAP, S-265744, S/GSK1265744, cabotegravir LA, cabotegravir sodium Drug Class: Integrase Inhibitors Molecular Formula: C19 H17 F2 N3 O5 Registry Number: 1051375-10-0 (CAS) Ch...
Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.